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A retrospective analysis of the database from A Coronary
Disease Trial Investigating Outcome with Nifedipine (AC-
TION) evaluated the effectiveness of nifedipine gastro-
intestinal therapeutic system (GITS) (i) in combination
with renin angiotensin system (RAS) blockers and (ii) in
patients with isolated systolic hypertension (ISH). Ana-
lysed on an intention-to-treat basis, treatment groups were
compared by the log-rank test without adjustment for
covariates and hazard ratios with 95% CIs were obtained
using Cox proportional hazards models. Of 7665 rando-
mized patients, 1732 patients were receiving RAS blockade
at baseline, the addition of nifedipine GITS significantly
reduced any cardiovascular (CV) event ( 20%; Po0.05),
the composite of death, any CV event and revasculariza-
tion ( 16%; Po0.05) and coronary angiography ( 22%;
Po0.01). These benefits were achieved with relatively
small differences in systolic (3.2mmHg) and diastolic
blood pressure (BP) (2.3mmHg). In 2303 patients (30.0%)
who had ISH at baseline (1145 nifedipine GITS and 1158
placebo), nifedipine significantly reduced the primary
efficacy end point ( 18%; Po0.03), any CV event ( 22%;
Po0.01) and new heart failure ( 40%; Po0.01). The
benefits were associated with between-group differences
in achieved BP of 4.7 and 3.3mmHg for systolic and
diastolic BP, respectively. In summary, the lowest CV
event rates were seen in those receiving (i) the combina-
tion of RAS blockade and nifedipine GITS and (ii) in those
specifically treated for ISH.
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Introduction
Hypertension is a powerful and independent risk
factor for all clinical manifestations of atheromatous
cardiovascular (CV) disease including coronary
artery disease (CAD), stroke, peripheral vascular
disease and heart failure. Globally, these major
vascular diseases are projected to remain leading
causes of morbidity and mortality until at least
2030.
1–3 Although a number of clinical outcome trials
have shown that antihypertensive drug treatment,
either as monotherapy or combination therapy, is
particularly beneficial in patients with high CV risk
there is relatively little specific information about the
treatment of patients with hypertension and angina.
The drug treatment of CV diseases, including
hypertension and angina, is continually evolving
and refining in response to new information. For
example, in recent years and across the whole
spectrum of CAD and its sequelae, there has been
an increasing emphasis on the use of drugs that
block the renin angiotensin system (RAS) and ACE
inhibitor drugs are now recommended in the
treatment of angina even though they have no
intrinsic anti-anginal activity. Correspondingly, in
the treatment of hypertension there is increasing
emphasis on the use of combination treatments
4 and
on the importance of systolic blood pressure (BP) as
a treatment target.
5 With regard to the optimal
management of the patient with both hypertension
and angina a number of different targets require to
be addressed. These include
(i) risk factor modification, including BP control to
o130/80mmHg;
(ii) symptomatic improvement, that is reduced
frequency of anginal episodes and reduced
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www.nature.com/jhhintake of other medications, particularly short-
acting nitrates;
(iii) prognostic improvement—for example, reduced
morbidity (interventions and events) and im-
proved mortality.
Nifedipine is a well-established dihydropyridine
calcium channel blocker (CCB) that is widely used
for the treatment of hypertension and other CV
diseases. The gastrointestinal therapeutic system
(GITS) is a long-acting formulation of this com-
pound that has been studied in a number of clinical
trials. In one large randomized outcome trial in
hypertensive patients (INSIGHT), nifedipine GITS
was compared with co-amilozide and found to
be equally effective in preventing overall cardio-
and cerebro-vascular complications.
6 The placebo-
controlled ACTION (A Coronary Disease Trial
Investigating Outcome with Nifedipine GITS) trial
examined the effects of the same compound on
clinical outcomes in patients with stable sympto-
matic CAD. The principal conclusions were that
nifedipine GITS not only is safe in patients with
stable symptomatic coronary disease but also signi-
ficantly reduces the occurrence of new overt heart
failure and the need for coronary interventions.
7
Furthermore, in a subgroup analysis of the hyper-
tensive patients, who constituted 52% of the
ACTION study population, there were significantly
fewer morbid events and procedures in the patients
receiving nifedipine GITS.
8
The substantial clinical database from the AC-
TION study has afforded the opportunity to speci-
fically address some further, clinically relevant
issues by way of retrospective analysis. In particular,
the usefulness and effectiveness of treatment with
nifedipine GITS has been appraised with specific
respect to the management of patients with angina
and the following issues:
(i) Antihypertensive and outcome effectiveness of
nifedipine GITS in combination with drugs,
which block the RAS blockade.
(ii) Patients with isolated systolic hypertension
(ISH).
Patients and methods
The design, methods and main results of the
ACTION trial have been published in detail pre-
viously.
7,9 In brief, 7655 patients with angina
pectoris were randomized to receive either nifedi-
pine GITS (n¼3825) or matching placebo (3840).
In addition to angina, patients had to have either
a history of myocardial infarction, or proven angio-
graphic CAD or a positive exercise test or perfusion
defect. The left ventricular ejection fraction had to
be at least 40%. Detailed selection criteria and
definitions have been described elsewhere.
9 The
starting dose of nifedipine GITS or placebo was
30mg once daily, increasing to 60mg once daily
within 6 weeks. It is important to note that these
treatments were in addition to ‘best practice’ CV
therapy, with a follow-up period of almost 5 years.
This further analysis has explored the effective-
ness of treatment with nifedipine GITS on the
following clinical problems:
(i) The combination of calcium channel blockade
(with nifedipine) and RAS blockade (with ACE
inhibitor drugs or angiotensin receptor blocking
drugs).
(ii) ISH (systolic BP 4140 and diastolic BP
o90mmHg).
Statistical methods
The following composite outcomes were compared:
the combined rate of death from any cause,
myocardial infarction, refractory angina requiring
coronary angiography, new overt heart failure
requiring hospitalization and peripheral revascular-
ization (that is the ACTION primary end point for
efficacy); the combined rate of death from any cause,
myocardial infarction and debilitating stroke (that is
the ACTION primary end point for safety); any CV
event (that is the ACTION primary end point for
efficacy minus non-CV death); any death, CV event
or procedure (that is the ACTION primary end point
for efficacy plus coronary angiography, percuta-
neous coronary intervention and coronary bypass
surgery); and any vascular event or procedure (that
is the ACTION primary end point for efficacy minus
non-CV death and new overt heart failure, plus
percutaneous coronary intervention and coronary
bypass surgery).
All analyses for composite outcomes and clinical
e v e n t sw e r ep e r f o r m e do na ni n t e n t i o n - t o - t r e a tb a s i s .
Deaths of unknown cause were considered as CV.
Coronary angiography and percutaneous coronary
intervention on the same day were counted only as
percutaneous coronary intervention. Treatment groups
were compared by the log-rank test without adjust-
ment for covariates or interim analysis. Hazard ratios
with 95% confidence intervals were obtained using
Cox proportional hazards models with treatment
allocation as the only covariate.
Results
Combination of calcium channel blockade
and RAS blockade
Of 7665 patients started on study medication, 1732
(22.6%) were receiving RAS blockade (ACE inhibi-
tor or ARB) at baseline and 857 were randomized to
receive nifedipine GITS and 875 to placebo. The
baseline characteristics of these patients are given in
Table 1 and the data on the use of additional BP
lowering medication at baseline are given in Table 2.
The BP responses at baseline and at the end of
follow-up in the trial are given in Table 3. Figure 1,
shows the effects of nifedipine (relative to placebo)
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in patients receiving RAS blockade at baseline.
The salient results are also provided in summary
table in comparison with those of the whole study
population (Table 4).
As evidenced by 95% confidence intervals that
do not include ‘no effect’ (hazard ratio¼1), nifedi-
pine significantly reduced any CV event, the
composite of death, any CVevent and revasculariza-
tion and coronary angiography, in patients receiving
RAS blockade at baseline (Figure 1). There were also
reductions in the primary composite end points for
both efficacy and safety, by, respectively, 14 and 7%,
but these did not achieve statistical significance.
These benefits were achieved despite relatively
small differences between the groups in achieved
BP: by 3.2 for systolic and by 2.3mmHg for diastolic
BP (Table 3). The achieved BP differences were less
than those in the overall study population but
numerically all of the benefits with nifedipine GITS
were greater in the patients receiving RAS blockade
at baseline (Table 4).
Isolated systolic hypertension
Of 7665 patients started on study medication,
2303 (30.0%) had ISH at baseline and 1145 were
randomized to receive nifedipine GITS and 1158
to placebo. The baseline characteristics of these
patients are given in Table 5 and the data on the use
of additional BP lowering medication at baseline are
given in Table 6. The BP responses at baseline and at
the end of follow-up in the trial are given in Table 7.
Figure 2 shows the effects of nifedipine (relative to
placebo) on pre-defined ACTION combined end
points in patients with ISH at baseline. The salient
results are also summarized in Table 4 in compar-
ison with those of the whole study population.
As evidenced by 95% confidence intervals that do
not include ‘no effect’ (hazard ratio¼1) (Figure 2),
nifedipine significantly reduced the hazard of most
of the combined end points. There were also
Table 1 Clinical characteristics of patients with RAS blockade
Nifedipine
(n¼857)
Placebo
(n¼875)
Demographics
Age (years) 63.8±8.8 63.7±9.2
Men 75.8% 76.6%
Clinical features
History of myocardial infarction 56.6% 57.5%
With coronary revascularization 27.5% 29.5%
Angiographic coronary artery
disease, no myocardial infarction
30.0% 30.2%
With coronary revascularization 17.5% 17.8%
Positive exercise or radionuclide
test only
13.2% 12.0%
No history of coronary artery disease 0.2% 0.3%
Significant lesions on coronary
angiogram
72.3% 73.0%
Past use of calcium antagonists 23.8% 20.8%
Current NYHA classes II–III 45.4% 42.6%
Anginal attacks 92.5% 91.9%
History of peripheral cardiovascular
disease
18.5% 17.0%
Risk factors
Current smoker 15.2% 14.3%
Total cholesterol X5.0mmoll
 1 61.4% 64.7%
Body mass index X30.0kgm
 2 27.8% 27.1%
Diabetes mellitus 22.7% 23.0%
Treated with insulin 4.6% 5.7%
Cardiovascular variables
Heart rate (beats per min) 65.8±10.5 66.8±10.9
Systolic blood pressure (mmHg) 142.7±20.0 143.1±18.9
Diastolic blood pressure (mmHg) 82.4±9.5 82.0±9.4
Abbreviation: RAS, renin angiotensin system.
Table 2 Use of concomitant treatments at baseline in patients
with RAS blockade
Nifedipine
(n¼857)
Placebo
(n¼875)
Antianginal drug
b blocker 71.7 (%) 72.9 (%)
Organic nitrate, as needed 48.0 (%) 48.9 (%)
Organic nitrate, daily maintenance 41.0 (%) 39.8 (%)
Other vasodilator 5.7 (%) 5.7 (%)
Any of the above 97.8 (%) 97.9 (%)
Any two of the above 44.2 (%) 45.6 (%)
Any three or four of the above 11.8 (%) 11.6 (%)
Lipid lowering
Statin 62.0 (%) 63.1 (%)
Fibrate 7.9 (%) 7.5 (%)
Other 0.9 (%) 1.4 (%)
Any of the above 68.8 (%) 69.2 (%)
Blood pressure lowering
ACE inhibitor 89.7 (%) 89.9 (%)
Angiotensin-II antagonist 10.3 (%) 10.1 (%)
Diuretic 20.3 (%) 23.3 (%)
Other 3.6 (%) 2.5 (%)
Any of the above 100 (%) 100 (%)
Other cardiovascular
Acetylsalicylic acid 85.4 (%) 84.8 (%)
Vitamin K antagonist 4.8 (%) 5.1 (%)
Cardiac glycoside 1.1 (%) 1.8 (%)
Amiodarone, sotalol or other
antiarrhythmic
4.1 (%) 5.1 (%)
Abbreviation: RAS, renin angiotensin system.
Table 3 The BP responses to nifedipine and placebo in patients
receiving RAS blockade (visit 18¼4 years treatment)
Nifedipine
SBP
Placebo
SBP
Nifedipine
DBP
Placebo
DBP
Visit 0 n¼857 n¼875 n¼857 n¼875
Mean 142.7±19.9 143.1±18.9 82.4±9.5 82.1±9.4
Visit 18 n¼679 n¼699 n¼679 n¼699
Mean 135.2±18.5 139.0±18.9 77.5±9.4 79.5±9.7
Mean
difference
 7.0±22.0  3.8±21.0  4.8±11.2  2.5±11.2
Abbreviations: BP, blood pressure; RAS, renin angiotensin system.
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(by 11%) and in debilitating stroke (by 16%) but
these did not achieve statistical significance. These
benefits were associated with differences between
the groups in achieved BP: by 4.7 for systolic and by
3.3mmHg for diastolic BP (Table 7). The achieved
BP differences were comparable with those in the
overall study population but the magnitude of
the achieved benefit was greater in the patients
with ISH (Table 4).
Discussion
The salient findings from these further analyses are
that, relative to the ACTION population as a whole,
the lowest rates for CV events were seen when
treatment with nifedipine GITS was (i) combined
with RAS blockade and (ii) applied to patients
with ISH. Of themselves these findings are perhaps
not surprising, particularly to the hypertension
specialists, but the relevance of ‘tight’ control of
(systolic) BP and the requirement in this patient
population for other agents in addition to ACE
inhibition appear to be only slowly influencing
HR (95% CI)
Favours nifedipine Favours placebo
4 . 1 1 4 . 0
HR (95% CI)    p=     
0.86 (0.71,1.05)  n.s.
0.93 (0.73,1.18)  n.s.
0.80 (0.65,0.99)  0.040
0.84 (0.73,0.98)  0.024
0.88 (0.74,1.05)  n.s.
0.40 (0.23,0.71)  0.001
0.70 (0.39,1.23)  n.s.
0.78 (0.64,0.94)  0.010
Primary Endpoint -Efficacy
Primary Endpoint -Safety
Any CV Event
Death, any CV Event or
Revascularisation
Revascularisation
Any Vascular Event or
Heart Failure
Debilitating Stroke
Coronary Angiography
0.8
Favours nifedipine Favours placebo
Figure 1 The effect of nifedipine GITS on pre-defined end
points in patients receiving RAS blockade at baseline.
Table 4 Relative incidence of end points (nifedipine vs placebo) compared to the overall patient population in ACTION in patients (A)
receiving RAS blockade and (B) with isolated systolic hypertension (ISH)
(A) ACEI/ARB
patients (n¼1732)
ACTION
patients (n¼7655)
(B) ISH patients
(n¼2343)
Primary end point  14% (NS)  3% (NS)  18% (Po0.03)
Secondary end points
Any CV event  20% (Po0.05)  6% (NS)  22% (Po0.01)
CV event, death, procedure  16% (Po0.05)  11% (Po0.02)  16% (Po0.01)
CV event, procedure  12% (NS)  9% (Po0.03)  18% (Po0.01)
Individual end points
BP reduction (mmHg) 3.2/2.3 4.6/2.7 4.7/3.3
New heart failure  60% (Po0.002)  29% (Po0.015)  40% (Po0.01)
Debilitating stroke  30% (NS)  22% (NS)  16% (NS)
Coronary angiography  22% (Po0.01)  18% (Po0.0001)  17% (Po0.03)
Refractory angina  15% (NS)  14% (NS)  23% (oNS)
Abbreviations: ACTION, A Coronary Disease Trial Investigating Outcome with Nifedipine; BP, blood pressure; CV, cardiovascular; RAS, renin
angiotensin system.
Table 5 Clinical characteristics of patients with isolated systolic
hypertension
Nifedipine
(n¼1145)
Placebo
(n¼1158)
Demographics
Age (years) 66.8±8.2 66.3±8.6
Men 74.4% 73.7%
Clinical features
History of myocardial infarction 49.3% 45.0%
With coronary revascularization 22.8% 22.9%
Angiographic coronary artery disease,
no myocardial infarction
32.7% 34.5%
With coronary revascularization 21.0% 22.1%
Positive exercise or radionuclide test
only
17.7% 19.6%
No history of coronary artery disease 0.3% 0.8%
Significant lesions on coronary
angiogram
65.5% 66.2%
Past use of calcium antagonists 23.6% 23.3%
Current NYHA classes II–III 46.8% 49.1%
Anginal attacks 92.7% 92.7%
History of peripheral cardiovascular
disease
18.4% 18.7%
Risk factors
Current smoker 14.7% 14.2%
Total cholesterol X5.0mmoll
 1 63.2% 61.9%
Body-mass index X30.0kgm
 2 22.8% 23.9%
Diabetes mellitus 19.9% 17.5%
Treated with insulin 2.1% 3.9%
Cardiovascular variables
Heart rate (beats per min) 64.1±10.3 64.1±10.2
Systolic blood pressure (mmHg) 148.9±10.5 150.0±11.1
Diastolic blood pressure (mmHg) 79.0±5.7 79.1±6.0
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practitioners.
For example, since the publication of the HOPE
trial in 2000
10 there has been a widespread percep-
tion that treatment with ACE inhibitor drugs and
ramipril, in particular, is selectively beneficial in the
treatment of patients with established CAD and that
these benefits are not attributable to BP lowering
alone. This position has been sustained despite the
less convincing findings of the EUROPA
11 and
PEACE
12 trials. However, since the publication of
HOPE, an important additional consideration is that
the ‘standard’ therapy for CAD has become more
intensive; thus, for example, some of the differences
between the results of HOPE and those of PEACE
may be explained by more intensive prior drug
treatment and better risk factor control in the PEACE
population. These baseline differences obviously
would reduce the likelihood of a relatively well-
treated, low-risk population benefitting from addi-
tional ACE inhibitor treatment, as in the PEACE
trial. The same interpretation can be applied to the
muted effectiveness of the angiotensin receptor
blocker, telmisartan, in the TRANSCEND study.
13
Against this background of evolving and improv-
ing treatment combinations, the present ACTION re-
analysis afforded the opportunity to assess whether
RAS blockade was definitively beneficial or whether
or not other treatments, specifically calcium chan-
nel blockade with nifedipine GITS, might offer
additional benefit in the subgroup of patients who
were already receiving ‘best practice’, ‘intensive’
treatment including RAS blockade (that is an ACE
inhibitor and/or angiotensin receptor blocker) at the
start of the trial (baseline). The results of this further
analysis identified that additional prognostic benefit
could be derived from the addition of nifedipine
GITS. These benefits were associated not only with
end points that have been shown earlier to be
predominantly associated with BP reduction, such
as heart failure,
14 but also with those that can be
attributed to the anti-ischaemic properties of nife-
dipine (for example, coronary angiography). The
overall trend was for greater reductions in all of the
end points in the patients receiving the combination
of RAS blockade and calcium channel blockade
(nifedipine GITS) than for the overall ACTION
population, despite a smaller differential BP reduc-
tion (Table 4). Thus, there is evidence to suggest that
a long-acting dihydropyridine CCB (nifedipine
GITS) may offer prognostic benefit in addition to
the symptomatic benefit, which is acknowledged in
treatment guidelines.
15
Table 6 Use of concomitant treatments at baseline in patients
with isolated systolic hypertension
Nifedipine
(n¼1145)
Placebo
(n¼1158)
Antianginal drug
b blocker 78.4 (%) 79.5 (%)
Organic nitrate, as needed 58.2 (%) 56.1 (%)
Organic nitrate, daily maintenance 36.9 (%) 37.0 (%)
Other vasodilator 4.4 (%) 3.7 (%)
Any of the above 98.6 (%) 98.3 (%)
Any two of the above 51.3 (%) 51.6 (%)
Any three or four of the above 13.9 (%) 13.1 (%)
Lipid lowering
Statin 60.0 (%) 57.4 (%)
Fibrate 5.6 (%) 6.5 (%)
Other 0.7 (%) 1.3 (%)
Any of the above 65.1 (%) 63.0 (%)
Blood pressure lowering
ACE inhibitor 21.8 (%) 23.8 (%)
Angiotensin-II antagonist 3.0 (%) 3.5 (%)
Diuretic 15.0 (%) 14.2 (%)
Other 2.8 (%) 1.8 (%)
Any of the above 34.9 (%) 35.6 (%)
Other cardiovascular
Acetylsalicylic acid 83.8 (%) 83.9 (%)
Vitamin K antagonist 4.9 (%) 4.9 (%)
Cardiac glycoside 0.9 (%) 1.1 (%)
Amiodarone, sotalol or other
antiarrhythmic
4.1 (%) 4.9 (%)
Table 7 The blood pressure responses to nifedipine and placebo
in patients with isolated systolic hypertension (visit 18¼4 years
treatment)
Nifedipine
SBP
Placebo
SBP
Nifedipine
DBP
Placebo
DBP
Visit 0 n¼1145 n¼1158 n¼1145 n¼1158
Mean 148.9±10.5 150.1±11.1 79.0±5.7 79.1±6.0
Visit 18 n¼933 n¼930 n¼933 n¼930
Mean 136.3±16.5 142.3±17.7 75.4±9.1 78.5±9.0
Mean difference  12.5±16.9  7.8±18.7  3.8±9.3  0.5±9.6
HR (95% CI)
Favours nifedipin Favours placebo
0.4 1.4 1
HR (95% CI)    p= 
0.82 (0.70,0.97)  0.021
0.89 (0.73,1.09) n.s
0.84 (0.74,0.96)  0.010
0.82 (0.70,0.95)  0.009
0.84 (0.52,1.36) n.s
0.83 (0.70,0.97)  0.021
Primary Endpoint -Efficacy
I
Primary Endpoint -Safety
Any CV Event
Death, any CV Event or
Revascularisation
0.8
0.78 (0.66,0.94)  0.007
0.60 (0.38,0.96)  0.031
Any Vascular Event or
Revascularisationr
Heart Failure
Debilitating Stroke
Coronary Angiography
Figure 2 The effect of nifedipine GITS on pre-defined end
points in patients with ISH at baseline.
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is ‘secondary’ prevention) are compatible with those
of two recent outcome studies in hypertension
(that is ‘primary’ prevention). The Anglo-Scandina-
vian Cardiac Outcomes Trial (ASCOT) compared a
CCB/ACE inhibitor (amlodipine/perindopril) regi-
men with a b blocker/diuretic (atenolol/bendroflu-
methazide) regimen and was stopped early on
the advice of the data safety monitoring board.
16
This decision was largely founded on the significant
benefits associated with the CCB/ACE-I that
were apparent for almost all of the secondary end
points: total CV events and procedures, all coronary
events, fatal and non-fatal stroke, CV mortality and
total mortality were all significantly reduced. The
ACCOMPLISH trial was a randomized, double
blind comparison of antihypertensive treatment
with the ACE inhibitor benazepril combined with
either the CCB amlodipine or the diuretic hydro-
chlorothiazide.
17 The group treated with the ACE
inhibitor–CCB combination had a relative risk
reduction of B20% in the primary end point, which
was a composite of morbidity and mortality from CV
causes. The secondary end point of death from CV
causes and non-fatal myocardial infarction and
stroke showed a similar benefit. In both ASCOT
and ACCOMPLISH there were imbalances in BP
control favouring the CCB-based regimens but in
both cases the authors provided evidence to suggest
that these pressure differences could not account for
the observed benefits.
16,17
The outcome benefits of treatment with dihydro-
pyridine CCBs were obviously established in a
number of randomized placebo-controlled trials in
hypertensive patients: these included STONE,
18
SYSTEUR
19 and SYST-CHINA.
20 The outcome
benefits of nifedipine GITS were specifically con-
firmed in INSIGHTin which there was no difference
in the primary composite end point in comparison
with co-amilozide.
6 In addition to lowering BP,
however, and before the publication of the ACTION
results, calcium channel blocking drugs (CCBs
were recognized treatments for the symptoms of
angina pectoris and were widely used for this
indication. The ACTION trial was designed and
conducted in response to the debate in the 1990s
about the safety of CCBs,
21,22 particularly in patients
with CAD, and it aimed to assess the effect of
nifedipine GITS on clinical outcomes in patients
with stable angina (regardless of the BP level at
baseline). A previous retrospective analysis from
ACTION confirmed that the benefits of nifedipine
GITS were particularly apparent in patients with
both CAD and hypertension and highlighted the
importance of BP control.
8 This previous analysis
did not address the specific issue of systolic
hypertension but it is perhaps indicative of the
perception by cardiologists of the importance of BP
control that ‘best’ practice (albeit from more than a
decade ago) permitted 52% of patients to have BP
4140/90mmHg. These present results not only
reinforce the previous observation that BP reduction
and BP control are important in patients with
angina but also extend this observation particularly
to patients with ISH (or persistent ISH despite
prior antihypertensive drug treatment). The main
finding is that nifedipine GITS significantly reduced
the incidence of the combined end points and
that these end point reductions were greater in the
ISH subgroup than those observed in the whole
ACTION trial population, despite a similar reduc-
tion in BP. These present findings are entirely
consistent with another analysis that indicated that
the benefits of nifedipine GITS can be attributed
both to its BP lowering effect and to its anti-anginal
properties.
14 The findings are also consistent
with those earlier studies with dihydropyridine
CCBs, which focused on ISH.
18–20 The analysis has
not specifically addressed the relationship between
BP reduction and the risk of CVevents but there was
no evidence of any deleterious effects of BP low-
ering in these patients with CAD and ISH and
nothing to support the concept of a J-shaped
relationship between BP reduction and the risk of
CV events.
23,24
In conclusion, the present analyses show that the
addition of nifedipine GITS to the treatment regi-
men of patients with symptomatic CAD who were
already receiving ACE inhibitors and/or angiotensin
receptor blockers results in a significant reduction of
CV morbidity. The interpretation of these analyses
must obviously be cautious as it is based on
subgroup analyses that effectively break the rando-
mization of the original study. Nonetheless, the
treatment groups in both analyses were well
matched with no statistical differences in either
their demographic features (Tables 1 and 5) or their
active treatments at baseline (Tables 2 and 6). This,
combined with the fact that there were no systema-
tic differences between the groups, leads to the
reasonable conclusion that the CV risk did not differ
between the groups and that the addition of the
long-acting CCB, nifedipine GITS, was effective not
only in improving BP control but also in reducing
major vascular events. These benefits were seen
even in patients who were already treated with ACE
inhibitors and/or angiotensin receptor blockers and
were particularly apparent in patients with poorly
controlled systolic BP.
It is well established that as an initial management
approach, optimal medical therapy without routine
PCI can be implemented safely in the majority of
patients with stable CAD.
25 Furthermore, time trend
analyses show a compelling need for more effective
management of risk factors in patients with coronary
heart disease.
26 Thus, there is a clear message of
practical clinical importance for the ‘best practice’
treatment of angina: ‘reliance’ on RAS blockade may
be misplaced and greater attention should be
directed towards control of BP (and particularly
systolic BP) by means, if necessary, of combinations
of BP lowering drugs.
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